310 related articles for article (PubMed ID: 12105162)
1. Allopurinol improves endothelial dysfunction in chronic heart failure.
Farquharson CA; Butler R; Hill A; Belch JJ; Struthers AD
Circulation; 2002 Jul; 106(2):221-6. PubMed ID: 12105162
[TBL] [Abstract][Full Text] [Related]
2. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.
Doehner W; Schoene N; Rauchhaus M; Leyva-Leon F; Pavitt DV; Reaveley DA; Schuler G; Coats AJ; Anker SD; Hambrecht R
Circulation; 2002 Jun; 105(22):2619-24. PubMed ID: 12045167
[TBL] [Abstract][Full Text] [Related]
3. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
George J; Carr E; Davies J; Belch JJ; Struthers A
Circulation; 2006 Dec; 114(23):2508-16. PubMed ID: 17130343
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.
Farquharson CA; Struthers AD
Circulation; 2000 Feb; 101(6):594-7. PubMed ID: 10673249
[TBL] [Abstract][Full Text] [Related]
5. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure.
Gavin AD; Struthers AD
Heart; 2005 Jun; 91(6):749-53. PubMed ID: 15894768
[TBL] [Abstract][Full Text] [Related]
6. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension.
Butler R; Morris AD; Belch JJ; Hill A; Struthers AD
Hypertension; 2000 Mar; 35(3):746-51. PubMed ID: 10720589
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris.
Rajendra NS; Ireland S; George J; Belch JJ; Lang CC; Struthers AD
J Am Coll Cardiol; 2011 Aug; 58(8):820-8. PubMed ID: 21835317
[TBL] [Abstract][Full Text] [Related]
8. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers.
Guthikonda S; Sinkey C; Barenz T; Haynes WG
Circulation; 2003 Jan; 107(3):416-21. PubMed ID: 12551865
[TBL] [Abstract][Full Text] [Related]
9. Allopurinol improves endothelial function in sleep apnoea: a randomised controlled study.
El Solh AA; Saliba R; Bosinski T; Grant BJ; Berbary E; Miller N
Eur Respir J; 2006 May; 27(5):997-1002. PubMed ID: 16707395
[TBL] [Abstract][Full Text] [Related]
10. Allopurinol and endothelial function in heart failure: future or fantasy?
Landmesser U; Drexler H
Circulation; 2002 Jul; 106(2):173-5. PubMed ID: 12105153
[No Abstract] [Full Text] [Related]
11. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters.
Greig D; Alcaino H; Castro PF; Garcia L; Verdejo HE; Navarro M; López R; Mellado R; Tapia F; Gabrielli LA; Nogerol C; Chiong M; Godoy I; Lavandero S
J Heart Lung Transplant; 2011 Apr; 30(4):408-13. PubMed ID: 21145258
[TBL] [Abstract][Full Text] [Related]
12. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress.
George J; Struthers AD
Vasc Health Risk Manag; 2009; 5(1):265-72. PubMed ID: 19436671
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.
O'Driscoll G; Green D; Taylor RR
Circulation; 1997 Mar; 95(5):1126-31. PubMed ID: 9054840
[TBL] [Abstract][Full Text] [Related]
14. Allopurinol and endothelial function: A systematic review with meta-analysis of randomized controlled trials.
Alem MM
Cardiovasc Ther; 2018 Aug; 36(4):e12432. PubMed ID: 29673103
[TBL] [Abstract][Full Text] [Related]
15. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide-dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects.
O'Driscoll JG; Green DJ; Rankin JM; Taylor RR
Clin Exp Pharmacol Physiol; 1999 Oct; 26(10):779-83. PubMed ID: 10549401
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure.
Fichtlscherer S; Rössig L; Breuer S; Vasa M; Dimmeler S; Zeiher AM
Circulation; 2001 Dec; 104(25):3023-5. PubMed ID: 11748093
[TBL] [Abstract][Full Text] [Related]
18. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
Tzemos N; Lim PO; MacDonald TM
Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes.
Darko D; Dornhorst A; Kelly FJ; Ritter JM; Chowienczyk PJ
Clin Sci (Lond); 2002 Oct; 103(4):339-44. PubMed ID: 12241530
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial.
von Haehling S; Schefold JC; Jankowska EA; Springer J; Vazir A; Kalra PR; Sandek A; Fauler G; Stojakovic T; Trauner M; Ponikowski P; Volk HD; Doehner W; Coats AJ; Poole-Wilson PA; Anker SD
J Am Coll Cardiol; 2012 Feb; 59(6):585-92. PubMed ID: 22300693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
